Screening of differently expressed genes in human prostate cancer cell lines with different metastasis potentials

Abstract

In order to screen the genes differentially expressed in two human prostate cancer cells with different metastasis potentials, suppression subtractive hybridization (SSH) was done twice on human prostate cancer cell line with high potential of metastasis PC3M-1E8 and its synogenetic cell line PC3M-2B4 with low metastasis potential. In the first subtraction PC3M-2B4 was used as tester and PC3M-1E8 as driver and the forward subtractive library was constructed. In the second on the tester and driver were interchanged and the reverse subtractive library was constructed. The screened clones of both libraries were sequenced and Gene Bank homology search was performed. Some clones were confirmed by quantitative real-time PCR. The results showed that two subtractive libraries containing 238 positive clones were constructed. Analysis of 16 sequenced clones randomly picked from two libraries showed that 4 differentially expressed gene fragments were identified as new EST with unknown functions. It was concluded that two subtractive libraries of human prostate cancer cell lines with different metastasis potentials were constructed successfully.

Keywords

prostate neoplasm / suppression subtractive hybridization / neoplasm metastasis / clone

References

[1] XiaT. L.. The Foundation And Clinic Of Prostate Cancer, 2000, Beijing, The Science Publishing House

[2] LiuX. Y., ZhengJ., FangW. G.. Isolation and characterization of human prostate cancer cell line subclones with different metastatic potential. Chin J Pathol (Chinese), 1999, 28(5): 361-364

[3] DiatchenkoL., LauY. F. C., CampbellA. P., et al.. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci, 1996, 93(3): 6025-6030

[4] YokotaJ.. Tumor progression and metastasis. Carcinogenesis, 2000, 21(3): 497-503

[5] HuangH., TindallD. J.. FOXO factors: a matter of life and death. Future Oncol, 2006, 2(1): 83-89

[6] JinG. S., KondoE., MiyakeT., et al.. Expression and intracellular localization of FKHRL1 in mammary gland neoplasms. Acta Med Okayama, 2004, 58(4): 197-205

[7] FrohlichE., SchlagenhauffB., MohrleM., et al.. Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer, 2002, 94(12): 3141-3149

[8] WerleB., KraftC., LahT. T., et al.. Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with non small cell lung carcinoma. Cancer, 2000, 89(11): 2282-2291

[9] SharmaM. R., KoltowskiL., OwnbeyR. T., et al.. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol, 2006, 81(2): 146-156

[10] EspositoJ., PenzelR., Chaib-HarrirecheM., et al.. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol, 2006, 208(5): 673-685

[11] LiuJ. W., ShenJ. J., TanzilloA., et al.. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene, 2003, 22(10): 1475-1485